← Eichor
Study identifier: NCT06576037 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Condition: Solid Tumor  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 1
Planned participants128
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

An open-label, Phase Ib dose escalation and dose expansion clinical trial evaluating the safety and efficacy of CBP-1019 combinations in patients with solid tumors of epithelial origin.

This description comes directly from the study's public registry record.

Talk to the study team

Siqing Fu, MD,PHD  ·  (713) 792-4318  ·  siqingfu@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06576037